NATHBIOGEN152.50

Nath Bio-Genes (India) Limited

· FMCG & Retail
₹ CrorePeersSARVESHWARINDOUSSUKHJITSKOHINOORAGRITECHREGAALBSHSLGULPOLYMcap ₹290 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)590.05547.03537.10537.10
Receivable Days (DSO)103.4988.9270.0470.04
Payable Days (DPO)110.92128.63156.31153.48
Cash Conversion Cycle (days)582.62507.32450.83453.66
Working Capital Turnover1.081.121.161.27
Asset Turnover0.380.360.410.41
Cash Conversion (CFO/Net Income)1.770.46-0.30-0.30
CFO/EBITDA1.410.35-0.24-0.24
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.